ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1955

Responsiveness and Minimal Important Difference of PROMIS Pain Interference, Fatigue, and Physical Function Forms in Adults with Idiopathic Inflammatory Myopathies

Didem Saygin1, Dana Direnzo2, Joost Raaphorst3, Jin Kyun Park4, Ingrid de Groot5, Clifton Bingham6, Ingrid Lundberg7, Malin Regardt8, catherine Sarver9, Marianne de Visser10, lara maxwell11, Dorcas Beaton12, Ju Yeon Kim13, Merrilee Needham14, Helene Alexanderson15, Lisa Christopher-Stine6 and Christopher Mecoli16, 1University of Pittsburgh, Pittsburgh, PA, 2University of Pennsylvania, Bala Cynwyd, PA, 3Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, 4Seoul National University Hospital and College of Medicine, Seoul, South Korea, 5N/A, Amsterdam, Netherlands, 6Johns Hopkins University, Baltimore, MD, 7Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Stockholm, Sweden, 8Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, 9N/A, Baltimore, MD, 10University of Amsterdam, Amsterdam, Netherlands, 11University of Ottawa, Ottawa, ON, Canada, 12Institute for Work & Health, Toronto, ON, Canada, 13Seoul National University Hospital, Seoul, South Korea, 14IIID Murdoch University and University of Notre Dame, Perth, Australia, 15Karolinska Institutet, Stockholm, Sweden, 16Johns Hopkins University School of Medicine, Baltimore, MD

Meeting: ACR Convergence 2023

Keywords: Myositis, OMERACT, Patient reported outcomes

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1945–1972) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Patient reported outcome measures (PROMs) are critical in assessing clinical outcomes. There is a paucity of PROMs for use in patients with adult idiopathic inflammatory myopathies (IIM). The Outcome Measures in Rheumatology (OMERACT) Myositis Working Group was established to develop validated PROMs for adult IIM. Our previous work has included identifying the domains of interest as pain interference, fatigue, and physical function and demonstrating the content validity, test-retest reliability, and construct validity of the PROMIS pain interference (6a), fatigue (7a), and physical function (8b) instruments. In this study, our goal was to assess the responsiveness and minimal important difference of these instruments in a prospective longitudinal cohort of adults with IIM.

Methods: Adults with IIM who were seen in the outpatient clinics in United States of America (USA), Netherlands, South Korea, Sweden, and Australia, were enrolled in this prospective observational study with two study visits. Relevant myositis core set measures (manual muscle testing [MMT8, 0-80], physician and patient global disease activity [0-10]), and the PROMIS instruments for pain interference (6a), fatigue (7a), and physical function (8b) were collected at the baseline and follow-up visits. Domain-specific anchor questions for symptoms of pain, fatigue, and physical function were asked at the follow-up visit (a lot better, a little better, stable, a little worse, a lot worse). Responsiveness of the PROMIS instruments was assessed using i) ANOVA to compare the scores across the anchor categories (worsened, stable, improved), ii) paired t test, effect size and standardized response mean for within-person score change, and iii) Pearson correlation with myositis outcome measures. Effect size was interpreted as small for < 0.2, medium for 0.2-0.5, and large for >0.5. Minimal important difference was calculated using the anchor-based method.

Results: 114 patients with IIM (median age of 60 [50-70], 60% female) completed two study visits at five international sites (USA [32.5%], Netherlands [23.7%], Korea [21.9%], Sweden [18.4%], Australia [3.5%])(Table 1). Changes in PROMIS pain interference, fatigue, and physical function were significantly different among anchor categories (Figure 1). Patients who reported improvement in domain-specific anchor questions had a significant improvement in their PROMIS scores with at least medium effect size ( >0.5), while patients who reported worsening and stability in anchor questions did not show a significant change with weak effect size (< 0.2) (Table 2). PROMIS instruments had weak to moderate correlations with MMT, patient and physician global. Using the anchor-based method, the minimal important difference was 2.7 t-score for PROMIS pain interference, 4 for fatigue, and 3.3 for physical function.

Conclusion: This study provides evidence towards the responsiveness of the PROMIS instruments in a large international prospective cohort of adults with IIM supporting their use as PROMs in adult myositis. Further work is planned to examine responsiveness in a larger cohort of those who worsen and in clinical trials.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: D. Saygin: None; D. Direnzo: None; J. Raaphorst: None; J. Park: None; I. de Groot: None; C. Bingham: AbbVie/Abbott, 2, Bristol-Myers Squibb(BMS), 5, Eli Lilly, 2, Janssen, 2, Pfizer, 2, Sanofi, 2; I. Lundberg: Argenx, 6, Astra-Zeneca, 5, Boehringer-Ingelheim, 6, Bristol-Myers Squibb(BMS), 1, Corbus Pharmaceutical, 6, EMD Serono Research & Development Institute, 6, Janssen, 6, Kezar, 6, Novartis, 11, Octapharma, 6, Orphazyme, 6, Pfizer, 1, Roche, 11, Xencor, 6; M. Regardt: None; c. Sarver: None; M. de Visser: Argenx, 1, 2, Novartis, 2; l. maxwell: None; D. Beaton: None; J. Kim: None; M. Needham: Abcuro, 6, Biogen, 6, Sanofi-Aventis, 6, Teva, 6; H. Alexanderson: None; L. Christopher-Stine: None; C. Mecoli: None.

To cite this abstract in AMA style:

Saygin D, Direnzo D, Raaphorst J, Park J, de Groot I, Bingham C, Lundberg I, Regardt M, Sarver c, de Visser M, maxwell l, Beaton D, Kim J, Needham M, Alexanderson H, Christopher-Stine L, Mecoli C. Responsiveness and Minimal Important Difference of PROMIS Pain Interference, Fatigue, and Physical Function Forms in Adults with Idiopathic Inflammatory Myopathies [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/responsiveness-and-minimal-important-difference-of-promis-pain-interference-fatigue-and-physical-function-forms-in-adults-with-idiopathic-inflammatory-myopathies/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/responsiveness-and-minimal-important-difference-of-promis-pain-interference-fatigue-and-physical-function-forms-in-adults-with-idiopathic-inflammatory-myopathies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology